Mutations in RAS oncogenes, present in approximately 10% to 15% of AML cases, include activating alterations in NRAS, KRAS, PTPN11, and NF1, which lead to abnormal proliferative signaling through the MAPK and PI3K pathways. The gene discussed is NRAS; the disease is acute myeloid leukemia.